Cardiol Therapeutics

Dilution score: 18/100 (LOW), 24.0 months cash

Short interest: 2.08% of float, squeeze risk: MODERATE

12576 PubMed publications found for Cardiol

Impact of left ventricular ejection fraction on outcomes with drug-coated balloons versus drug-eluting stents for de novo coronary artery disease.

Updates on Pathophysiology of Pericarditis to Guide Development of Therapeutics.

Sex-based effectiveness in buprenorphine/naloxone and methadone treatment for opioid use disorder: Findings from the OPTIMA trial.

Incidence of HIV and HCV Among People Who Inject Drugs in Montreal, Canada: Data From the HEPCO Longitudinal Cohort Study, 2011-2025.

Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial.

12575 PubMed publications found for Cardiol

Dilution score: 13/100 (LOW), 24.2 months cash

Short interest: 2.09% of float, squeeze risk: LOW

12573 PubMed publications found for Cardiol

12568 PubMed publications found for Cardiol

Ivabradine, Propranolol, and Placebo for Postural Orthostatic Tachycardia Syndrome (POTS): A Randomized Crossover Trial.

Effectiveness and Safety of Early Rhythm Control in Patients With Atrial Fibrillation and Chronic Kidney Disease.

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

Fatal Pulmonary Embolism in Professional Athletes: A Window Into a Broader VTE Problem.

Acute Performance of the DynamX Bioadaptor in Complex Coronary Lesions: An Optical Coherence Tomography-based Evaluation.

Short interest: 2.04% of float, squeeze risk: LOW

12565 PubMed publications found for Cardiol

Dilution score: 17/100 (LOW), 19.7 months cash

Short interest: 2.05% of float, squeeze risk: MODERATE

12552 PubMed publications found for Cardiol

Single-Pill Combination Therapy for Hypertension: Persistent Underuse in the United States, 2015-2025.

Prospective Multicenter Evaluation of a Novel Active Driving System for Pediatric Ventricular Assist Device Support.

Drug-eluting balloons versus drug-eluting for de novo coronary lesions with large-vessel focus: a narrative review.

Tricuspid Valve Academic Research Consortium-2 (TVARC-2): Trial Design and Endpoints.

12551 PubMed publications found for Cardiol

Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.

12548 PubMed publications found for Cardiol

Cardiovascular Trials in Hemodialysis: Closing the Evidence Gap.

Integrating Findings Into Practice: Assessing External Validity of Congestive Heart Failure Trials.

Tricuspid Valve Academic Research Consortium-2 (TVARC-2) Tricuspid Valve: Trial Design and Endpoints.

12547 PubMed publications found for Cardiol

<article class="bts-verified-summary" data-ticker="CRDL">
<p>Cardiol Therapeutics (CRDL) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 1 Phase 3<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>Trial NCT06708299<sup><a href="#fn-3">[3]</a></sup> evaluates CardiolRx in Recurrent Pericarditis with a target enrollment of 110 participants.</p>
<p>No Form 4 insider filings for CRDL were recorded at the SEC in the past 30 days<sup><a href="#fn-4">[4]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Cardiol+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Cardiol+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">ClinicalTrials.gov · NCT06708299 (2026-03-13) <a href="https://clinicaltrials.gov/study/NCT06708299" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-4">SEC EDGAR · 0001702123 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22CRDL%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

ClinicalTrials.gov — NCT06708299

SEC EDGAR — 0001702123

Cardiol Therapeutics (CRDL) — BioTechSigns Verified Summary

Cardiol Therapeutics (CRDL) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 3[1].

Trial NCT06708299[3] evaluates CardiolRx in Recurrent Pericarditis with a target enrollment of 110 participants.

No Form 4 insider filings for CRDL were recorded at the SEC in the past 30 days[4].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Cardiol+Therapeutics%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Cardiol+Therapeutics%22&aggFilters=status%3Arec%2Cact
[3] ClinicalTrials.gov, NCT06708299. Source last updated 2026-03-13, retrieved 2026-04-11.
    https://clinicaltrials.gov/study/NCT06708299
[4] SEC EDGAR, 0001702123. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22CRDL%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation.

Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks.

The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.